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Background: The effects of paclitaxel-eluting balloon (PEB) on ﬂow limiting intact
plaques, healing processes and plaque remodeling at long term are not known. Aim of
this exploratory study was to assess the long-term coronary arterial response to DEB
using serial VH-IVUS.
Methods: Patients with de novo signiﬁcant A/B lesion type in vessels with diameter >
2,5mm and £ 3,5mm were enrolled. Major exclusion criteria were in-stent restenosis
and STEMI patients. Lesion of interest was predilated and then treated with PEB
(Dior, Eurocor) with a RVD/balloon diameter ratio of 1. Patients who received bail-
out stenting were excluded. VH-IVUS data were acquired before the predilation and at
4-month FU. Primary objective was to assess the change in % atheroma volume
(PAV) and necrotic core (NC) volume from baseline to FU in the entire lesion.
Secondary objectives were change from baseline in: VH plaque type, lumen area (LA)
and plaque burden at the MLA site.
Results: A total of 23 were screened, but eventually18 patients were enrolled in the
study. Mostly, the target vessel was RCA (66.7% of cases). Mean DEB diameter and
length were 30.41 and 19.33.9 respectively. Serial IVUS data at baseline and at
4-month FU are reported in Table 1. In the entire lesion, PAV and NC volume did not
change signiﬁcantly, while at the MLA site, LA increased and plaque burden
diminished as a result of a signiﬁcant increase in EEM area. Remodeling index
changed from 0.930.17 to 1.090.17 (p 0.00019). VH Thin Capped Fibroatheromas
(TCFAs) signiﬁcantly decreased from 7 to 2 changing into more stable plaque
phenotypes (ThCFA and PIT).Baseline (n=18)
4-month follow-up
(n=18) P value
Lumen area (mm2) 2.50.7 3.61.2 0.0038
EEM area (mm2) 10.64.0 12.74.6 0.0017
Plaque burden (%) 74.98.1 69.98.3 0.0283
Remodeling index 0.930.17 1.090.17 0.0019
Lesion length (mm) 9.83.9 10.53.2 0.1860
PAV (%) 62.29.0 59.58.8 0.1256
NC (%) 21.37.2 22.07.8 0.7035
FF (%) 10.04.1 9.13.7 0.4856
FT (%) 62.09.8 60.810.9 0.5048
DC (%) 7.16.0 8.07.7 0.4975
TCFA, n (%) 7 (38.8) 2 (11.1)
ThCFA, n (%) 8 (44.4) 13 (72.2)
PIT, n (%) 3 (16.6) 2 (11.1)
Fibrotic/
Fibrocalciﬁc, n (%)
0/0 0/1 (5.5)
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SConclusions: PCI with DEB was not associated with a signiﬁcant change in PAV and
NC volume over time. However, TCFAs changed their phenotype into a more stable
looking one. This hypothesis generating study might serve as a basis for exploring
further the plaque sealing concept in a larger study.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-591
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Background: We hypothesized that biodegradable polymer siroimus-eluting stents
(BP-SES) might enhance vascular healing as compared to permanent polymer ever-
olimus-eluting stents (PP-EES). Accordingly we compared the healing patterns of BP-
SES (Osiro) with PP-EES (Xience) using optical coherence tomography (OCT).
Methods: A total of 60 patients undergoing coronary intervention for de novo
stenoses were randomly assigned to BP-SES or PP-EES in 1:1 allocation. Tissue
coverage, stent apposition and neointimal maturity were assessed using OCT at 6-8
months.
Results: Both stents showed marked heterogeneity in vascular healing. After
adjustment for strut-level clustering with a mixed linear model approach, there were
no statistical differences in the rates of uncovered struts between BP-SES and PP-EES
(8.3% [95%CI: 0.6-56.8%] vs. 3.9% [95%CI: 0-81.7%] in PP-EES, p¼.41, Figure A).
A total of 0.1% of struts were malapposed in BP-SES group and 0.4% of struts in PP-
EES group (p¼.42). In patient-level analysis, 2 patients in BP-SES group versus 3 in
PP-EES group had >30% of uncovered struts, respectively (p¼.52). Neointimal
volume obstruction was 8.8% [5.8-14.0] in BP-SES versus 11.2% [8.0-23.5] in PP-
EES (p¼.15, Figure B).
Conclusions: No signiﬁcant differences in tissue coverage were detected by OCT
between BP-SES and PP-EES. Marked heterogeneity of healing was observed in both
groups.TCT-592
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Background: Fully bioresorbable scaffolds (BRS) are a novel approach of treatment
for coronary narrowing that provides transient vessel support with drug delivery
capability without the long-term limitations of metallic drug-eluting stents. However,
a potential drawback of the bioresorbable scaffold is the potential for disruption of the
strut network when over-expanded. Conversely, the structural discontinuity of the
polymeric struts at a late stage is a biologically programmed fate of the scaffold during
the course of bioresorption.
Methods: The ABSORB Cohort B trial is a multicentre single-arm trial assessing the
safety and performance of the Absorb BVS (second generation, Abbott Vascular,acts/POSTER/Intravascular Imaging and PCI B179
